Ask AI
ProCE Banner Activity

CE

Transforming Cardiorenal Care: Nurse-Led Strategies for Heart Failure Management With SGLT2 Inhibitors

Video

On-demand webcast of expert faculty presentation and nurse-led strategies to improve heart failure care through guideline-directed medical therapy, including SGLT2 inhibitors.

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: June 23, 2025

Expiration: June 22, 2026

Continue Activity

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners)

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This activity is intended for cardiology nurses and nurse practitioners, including those specializing in heart failure, who care for patients with heart failure.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Heart Failure.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Identify gaps in heart failure management guideline-directed medical therapy to improve patient outcomes

  • Assess the benefits and safety of early and long-term use of SGLT2 inhibitors in heart failure care, focusing on their role in improving cardiovascular outcomes for eligible patients

  • Formulate nurse-led strategies to incorporate SGLT2 inhibitors into patient-centered treatment plans considering diverse presentations of left ventricular ejection fraction

Disclosure

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Midge Bowers, DNP, FNP-BC, FAANP, FAAN, FACC, has no relevant financial relationships to disclose.

Stephen J. Greene, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Corcept, CSL Vifor, Idorsia, Lexicon, Lilly, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Recordati, Sanofi, SCPharmaceuticals, Sumitomo, Tricog Health; researcher: Bayer, Boehringer Ingelheim, Novartis.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 23, 2025, through June 22, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.